Joseph Gibbons, Merrill J Egorin, Ramesh K Ramanathan, Pingfu Fu, Daniel L Mulkerin, Stephen Shibata, Chris H M Takimoto, Sridhar Mani, Patricia A LoRusso, Jean L Grem, Anna Pavlick, Heinz-Josef Lenz, Susan M Flick, Sherrie Reynolds, Theodore F Lagattuta, Robert A Parise, Yanfeng Wang, Anthony J Murgo, S Percy Ivy, Scot C Remick
PURPOSE: This study was undertaken to determine the safety, dose-limiting toxicities (DLT), maximum-tolerated dose (MTD), and pharmacokinetics of imatinib in cancer patients with renal impairment and to develop dosing guidelines for imatinib in such patients. PATIENTS AND METHODS: Sixty adult patients with advanced solid tumors and varying renal function (normal, creatinine clearance [CrCL] >or= 60 mL/min; mild dysfunction, CrCL 40 to 59 mL/min; moderate dysfunction, CrCL 20 to 39 mL/min; and severe dysfunction, CrCL < 20 mL/min) received daily imatinib doses of 100 to 800 mg...
February 1, 2008: Journal of Clinical Oncology